2022
Highlights from the 2022 ASCO gastrointestinal cancer symposium: An overview by the EORTC gastrointestinal tract cancer group
SCLAFANI, Francesco, Elisa FONTANA, Lucjan WYRWICZ, Anna Dorothea WAGNER, Juan W VALLE et. al.Základní údaje
Originální název
Highlights from the 2022 ASCO gastrointestinal cancer symposium: An overview by the EORTC gastrointestinal tract cancer group
Autoři
SCLAFANI, Francesco (garant), Elisa FONTANA, Lucjan WYRWICZ, Anna Dorothea WAGNER, Juan W VALLE, Elizabeth SMYTH, Mark PEETERS, Radka OBERMANNOVÁ (203 Česká republika, domácí), Cindy NEUZILLET, Manfred P LUTZ, Thibaud KOESSLER, Irit BEN-AHARON, Dirk ARNOLD, Maria ALSINA a Markus MOEHLER
Vydání
CLINICAL COLORECTAL CANCER, DALLAS, CIG MEDIA GROUP, LP, 2022, 1533-0028
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30204 Oncology
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 3.400
Kód RIV
RIV/00216224:14110/22:00128356
Organizační jednotka
Lékařská fakulta
UT WoS
000898614900008
Klíčová slova anglicky
Clinical trials; Meeting; Esophago-gastric cancers; Hepato-pancreatico-biliary cancers; Colorectal cancers
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 30. 1. 2023 12:51, Mgr. Tereza Miškechová
Anotace
V originále
Recently, we have witnessed impressive diagnostic and therapeutic changes for gastrointestinal cancer patients. New challenges brought by the COVID-19 pandemic have led us to re-evaluate our work priorities. Thanks to the commendable resilience of both investigators and patients, however, clinical research never stopped. In addition to conducting cutting-edge research and serving patients' needs, as EORTC Gastrointestinal Tract Cancer Group, we are committed to pursuing educational initiatives beneficial to the entire European oncology community and beyond. In this regard, we have been providing critical discussions of new data from major international meetings. In this article, we discuss results of important selected studies presented at the 2022 ASCO Gastrointestinal Cancer Symposium, putting them in perspectives and highlighting potential implications for routine practice. With the number of in-person attendees and practice-changing/informing trials presented, this meeting represented a milestone in the return to normality as well as in the fight against cancer.